Get started
Author

Preeti Trisal

Humanized Anti-Trop-2 IgG-SN-38 Conjugate for Effective Treatment of Diverse Epithelial Cancers: Preclinical Studies in Human Cancer Xenograft Models and Monkeys
2011 · Thomas M. Cardillo, Serengulam V. Govindan, et al. · Clinical Cancer Research · 311
PDF
Sacituzumab Govitecan (IMMU-132), an Anti-Trop-2/SN-38 Antibody–Drug Conjugate: Characterization and Efficacy in Pancreatic, Gastric, and Other Cancers
2015 · Thomas M. Cardillo, Serengulam V. Govindan, et al. · Bioconjugate Chemistry · 304
Improving the Therapeutic Index in Cancer Therapy by Using Antibody–Drug Conjugates Designed with a Moderately Cytotoxic Drug
2014 · Serengulam V. Govindan, Thomas M. Cardillo, et al. · Molecular Pharmaceutics · 60
Combination lenalidomide‐rituximab immunotherapy activates anti‐tumour immunity and induces tumour cell death by complementary mechanisms of action in follicular lymphoma
2019 · Hsiling Chiu, Preeti Trisal, et al. · British Journal of Haematology · 48
PDF
Targeting both IGF-1R and mTOR synergistically inhibits growth of renal cell carcinoma in vitro
2013 · Thomas M Cardillo, Preeti Trisal, et al. · BMC Cancer · 33
PDF
Follicular lymphoma comprises germinal center–like and memory-like molecular subtypes with prognostic significance
2024 · Camille Laurent, Preeti Trisal, et al. · Blood · 18
PDF
Evaluation of a Novel Hexavalent Humanized Anti-IGF-1R Antibody and Its Bivalent Parental IgG in Diverse Cancer Cell Lines
2012 · Chien-Hsing Chang, Yang Wang, et al. · PLoS ONE · 9
PDF
Characterization of an anti-Trop-2-SN-38 antibody-drug conjugate (IMMU-132) with potent activity against solid cancers.
2014 · David M. Goldenberg, Edmund A Rossi, et al. · Journal of Clinical Oncology · 5
Combination of Lenalidomide and Rituximab (R2) Targets Immune Dysfunction in FL By Activating T and NK Cells Ex Vivo and Is Differentiated from Chemotherapy
2017 · Hsiling Chiu, Patrick R. Hagner, et al. · Blood · 3
Abstract 5345: Potent ribonuclease-based immunotoxins comprising quadruple ranpirnase (Rap) site-specifically conjugated to B-cell lymphoma-targeting antibodies
2010 · Edmund A. Rossi, Eric Chan, et al. · Cancer Research · 3
Identification of an activated/memory B‐cell signature of poor outcome and sensitivity to lenalidomide in follicular lymphoma patients
2023 · C. Laurent, P. Trisal, et al. · Hematological Oncology · 2
PDF
Topic Modeling of Genotyping of Transcriptomes Reveals Collaboration between BTKC481S-Mutant and Wild Type Cells in Btki-Resistant Chronic Lymphocytic Leukemia
2024 · Ramon Massoni-Badosa, Joshua S. Schiffman, et al. · Blood · 1
PDF
First-in-human study to evaluate the safety, tolerability, and PK of EIK1005, a novel WRN inhibitor in healthy participants.
2026 · Philip Ryan, Carolyn Cho, et al. · Journal of Clinical Oncology
Biomarkers and Methods of Treatment of Follicular Lymphoma
2024 · Huang Chong, Chris, Stokes, Matthew, et al. · HAL AMU
Abstract LB345: Correlating the blood immune repertoire and clinical features of del17p CLL patients
2024 · Ethan J. Katcher, Kim A. Gwin, et al. · Cancer Research
High Deletion Burden Identified By Whole Genome Sequencing Is Associated with Enhanced Risk in del17p CLL Patients
2023 · Preeti Trisal, Esteban Braggio, et al. · Blood
PDF
Data from Humanized Anti-Trop-2 IgG-SN-38 Conjugate for Effective Treatment of Diverse Epithelial Cancers: Preclinical Studies in Human Cancer Xenograft Models and Monkeys
2023 · Thomas M. Cardillo, Serengulam V. Govindan, et al.
Data from Humanized Anti-Trop-2 IgG-SN-38 Conjugate for Effective Treatment of Diverse Epithelial Cancers: Preclinical Studies in Human Cancer Xenograft Models and Monkeys
2023 · Thomas M. Cardillo, Serengulam V. Govindan, et al.
Supplementary Data from Humanized Anti-Trop-2 IgG-SN-38 Conjugate for Effective Treatment of Diverse Epithelial Cancers: Preclinical Studies in Human Cancer Xenograft Models and Monkeys
2023 · Thomas M. Cardillo, Serengulam V. Govindan, et al.
Supplementary Data from Humanized Anti-Trop-2 IgG-SN-38 Conjugate for Effective Treatment of Diverse Epithelial Cancers: Preclinical Studies in Human Cancer Xenograft Models and Monkeys
2023 · Thomas M. Cardillo, Serengulam V. Govindan, et al.
PDF
Single-Cell Multi-Omics Reveals Distinct Paths to Survival of Admixed BTKC481 Mutant Vs. Wild-Type Cells in Clinically Progressing Chronic Lymphocytic Leukemia
2020 · Andrew Lipsky, Danny Luan, et al. · Blood
Abstract 4402: The anti-tumor effects of two novel multivalent/multifunctional agents derived from hR1, a humanized anti-insulin-like growth factor receptor-I monoclonal antibody, are enhanced in renal cell carcinoma and synergistic with an mTOR inhibitor
2012 · Thomas M. Cardillo, Anju Nair, et al. · Cancer Research
P3-02-01: A Novel Bispecific, Hexavalent, Antibody (HexAb) Inhibits Anchorage-Independent Growth and Reduces Invasiveness of Triple-Negative Breast Cancer Cell Lines In Vitro.
2011 · DM Goldenberg, Y Wang, et al. · Cancer Research
Abstract 3619: Tolerability in mice, monkeys, and rabbits of new antibody (MAb)-drug (SN-38) immunoconjugates
2011 · David M. Goldenberg, Robert M. Sharkey, et al. · Cancer Research
A New Class of Dimeric α-Interferons (IFN-α) Made by the Dock and Lock (DNL) Method for Improved Cancer Therapy.
2007 · Edmund A. Rossi, William J. McBride, et al. · Blood
Works count: 27
Citation count: 797
H-index: 7
I10-index: 6
Year
Topic
Type